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Background
The reciprocal virological-immunological interactions
between HIV and HCV, as well as the reciprocal effect
of the specific antiviral therapies, are still poorly
known. A rare case report of spontaneous clearance of
HCV occurred in an ex-IVDA co-infected with HIV-
HCV since 20 years, and never treated for HCV, is
presented.
Methods
A 49-year-old ex-IVDA patient (p) tested HIV-HCV
positive since 1989, and was treated for HIV disease
since 1990 with limited compliance until 2 years ago.
He never attained undetectab l eH I Vv i r e m i au n t i lt h e
last 6 months, although CD4+ T-lymphocyte count stea-
dily remained >300 cells/μL.
Results
Until this last semester, against medical recommenda-
tion, our p continued alcohol consumption and irregu-
lar drug addict, despite an ongoing methadone
program. Serum transaminases showed fluctuating
values, always >2-3.5-fold normal levels, while HCV
replication was confirmed by values of 1,200-4,000 ×
10
3 IU/mL. During the last 6 months, our p first aban-
doned its former lamivudine-zidovudine-nevirapine
therapy, leading to a combination including 2 novel
nucleos(t)ide analogues (tenofovir-emtricitabine), asso-
ciated to the protease inhibitors (PI) lopinavir-ritona-
vir, and finally in the last 3 months due to
gastrointestinal intolerance-hypertriglyceridemia he
introduced fosamprenavir-ritonavir on behalf of lopina-
vir-ritonavir. Already after lopinavir-ritonavir use, our
p attained undetectable plasma HIV-RNA levels
(always confirmed thereafter), while CD4+ count
showed the greatest values even registered by our p
(513-662 cells/μL). During 2 subsequent controls, qua-
litative HCV viremia tested negative for the first time,
concurrently with normal transaminases.
Discussion
Single cases of apparent disappearance of a chronic
HCV infection in HIV-HCV co-infected p in absence
of anti-HCV therapy have been described as anecdotal
reports. In these episodes, a role of anti-HIV therapy
(without reference to speficic drugs and associations),
and that of a concurrent, significant immune recovery
was often claimed. The eventual role of HIV PI,
although a negligible direct anti-HCV is known, is still
debated, depending on the direct-indirect role possibly
played by PI in the dynemics of HIV-HCV co-infec-
tion. Fosamprenavir is a PI with contained liver toxi-
city, thus recommended just in p with a concomitant
chronic hepatis/liver cirrhosis. A systematic revision of
safety databases of fosamprenavir in HIV-infected p
with chronic viral hepatitis (to detect eventual virologi-
cal-immunological changes of the concomitant HCV
hepatitis), and a systematic appraisal of all literature
anecdotal case reports, may shed light on novel
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